Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

l trial for elagolix, the  most advanced clinical program in the Company's pipeline, will fail to support the additional Phase III clinical trial required for regulatory approval; risk that the elagolix Phase III program overall will encounter delays for regulatory or other reasons; risk that the elagolix Phase III clinical program will fail to demonstrate that elagolix is safe and effective for the treatment of endometriosis or support filings for regulatory approval; risk that the uterine fibroid elagolix clinical trials will fail to demonstrate that elagolix is safe and effective for the treatment of uterine fibroids; and  risks associated with the Company's dependence on corporate collaborators for Phase III development, commercial manufacturing and marketing and sales activities. In addition, the Company faces risks and uncertainties with respect to the rest of the Company's R & D pipeline including risk that the Company's clinical candidates will not be found to be safe and effective; risk that NBI-98854 will not proceed to later stage clinical trials and risk that the Company's clinical trials will fail to demonstrate that NBI-98854 is safe and effective; and risk that the Company's research programs will not identify pre-clinical candidates for further development. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's repor
'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
(Date:1/14/2014)... January 14, 2014 Date: Friday, April 11, ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... organization solely dedicated to finding a cure for hepatitis B ... will host its annual Crystal Ball on Friday, April 11 ...
(Date:1/14/2014)... 2014 Histogen, Inc., a regenerative medicine ... grown under simulated embryonic conditions, today announced that they ... Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary ... agreement is an amendment to the existing license between ...
(Date:1/14/2014)... BURLINGAME, Calif. , Jan. 14, 2014 As pet owners ... no doubt many of them wrote: "Take better care of my ... and even designer clothes and top-brand carrying cases to take the ... Pet parents might also feel compelled to buy some pricey toys ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... a regulatory framework to guide the approval of the ... providing more affordable treatment for millions of Americans suffering ... chairman and CEO of Medco Health Solutions, Inc. (NYSE: ... and innovation over a period of many years has ...
... CASTLE, Del., March 12 -- Arkion(R) Life Sciences has ... AV-1011 Liquid Rice Seed Treatment in Louisiana and Missouri ... The EPA approval means that rice growers in these ... grackles. The new bird repellent effectively stops birds ...
... States, long the beneficiary of talented immigrants, must act ... pursue expanding opportunities in their home countries, according to ... Science and Technology .In A Reverse Brain Drain ... Harvard Law School, writes that immigrant scientists and engineers, ...
Cached Biology Technology:Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions 2Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions 3AV-1011 Bird Repellent to Protect Rice Seed Approved for Use in Louisiana and Missouri 2U.S. Risks Losing Highly Skilled Immigrants 2U.S. Risks Losing Highly Skilled Immigrants 3
(Date:4/23/2014)... announced Sophie Martin of the University of Lausanne, Switzerland, ... The award acknowledges her work to understand the molecular ... cell. , Martin has been working for the past ... way in which the spatial organization of cells contributes ... 11 years, she has been using fission yeast, which ...
(Date:4/23/2014)... new study by a University of Exeter researcher has ... of wild camels thriving in Australia,s remote outback have ... scale. , Sarah Crowley, of the Environment and Sustainability ... the history of the camel in Australia, from their ... to their current status as unwelcome "invader." , The ...
(Date:4/23/2014)... a technique used to read quickly. It involves ... non-essential words and/ or sentences. Similarly to humans, ... quickly "read" genetic information. Genes that need to ... smaller the encoding message, the easier it will ... Instituto Gulbenkian de Cincia (IGC, Portugal) and Centre ...
Breaking Biology News(10 mins):EMBO Gold Medal 2014 awarded to Sophie Martin 2How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3Cell division speed influences gene architecture 2
... from North Carolina State University, the University of Washington ... most diverse collections of prehistoric non-native animal remains in ... find contributes to our understanding of culture in the ... may have been more important than previously thought. ...
... The Saint Louis Zoo,s Ron Goellner Center for ... on Nov. 30, 2011, that Ozark hellbenders have been ... subspecies of hellbender. This decade-long collaboration has yielded ... Nov. 15, and currently there are approximately 120 additional ...
... COPENHAGEN, DENMARK/ROCKVILLE, MD, USA Statens Serum Institut and Aeras ... trial of a new candidate TB vaccine designed to protect ... The trial is being conducted by the South African ... in the Western Cape province of South Africa. Dr. Hassan ...
Cached Biology News:Archaeologists find new evidence of animals being introduced to prehistoric Caribbean 2World's first captive breeding of Ozark hellbenders at Saint Louis Zoo 2World's first captive breeding of Ozark hellbenders at Saint Louis Zoo 3Vaccine targeting latent TB enters clinical testing 2
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation of endotoxins for research purposes. sensitivity 0.05-0.1 EU/mL...
... The Label IT siRNA Tracker Intracellular Localization ... directly label and deliver siRNA, of your ... for in vitro tracking experiments. Subcellular localization ... can be monitored following introduction of the ...
... MW: 60kDa (A) and 36kDa (C) ... pH 7.5, 500mM NaCl, 60mM 2-mercaptoethanol, ... 1mM DTT, and 0.1mg/ml serum albumin ... of proteins. Purification: DEAE chromatography, aminohexyl-agarose ...
... The Label IT siRNA Tracker Intracellular ... to directly label and deliver siRNA, of ... manner, for in vitro tracking experiments. Subcellular ... expression can be monitored following introduction of ...
Biology Products: